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Depicting the cellular and molecular bases of the continuous dialogue existing between the peripheral
immune and the central nervous systems, as in neurolupus, is fundamental to improve, and better
apprehend the role played by immune cells and mediators in the initiation and progression of neuro-
logical and psychiatric diseases, which nowadays remain a major public health issue. The relative fre-
quency of neurological symptoms occurring in systemic autoimmunity is particularly worrying as, for
example, two-thirds of patients with lupus will eventually experience the disabling effects of neuro-
psychiatric lupus. Neurolupus is a particularly severe form of lupus with wide-ranging symptoms, which
contribute to increased mortality and morbidity in patients. In this context, infections, which suddenly
trigger exacerbations of the otherwise mild lupus disease, may drive the progression of neuro-
inﬂammation and neurodegeneration via different mechanisms involving a network of effector mole-
cules and cells. The complex interaction of neuroimmunology and neuroinfectiology represents a
genuine challenge for basic scientists and clinicians to understand the mechanisms that are implicated,
and identify possible biomarkers of severity that might predict the development of this devastating form
of lupus. The ultimate goal is to design appropriate, personalised therapeutic strategies to improve the
outcome of the disease.
© 2016 Elsevier Ltd. All rights reserved.Contents
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It has long been established that neuropsychiatric (NP) diseases
can be elicited by infectious pathogens, diet, or environmental
components [1]. Despite intensive investigation, however, the
aetiology of most NP diseases as well as autoimmune diseases
(AIDs) remains elusive. The interplay of hormonal, immunological,
and environmental factors associated to a genetically-predisposed
ground appears to be central but nowadays, it is not known how
these intrinsic and extrinsic factors associate to trigger the disease,
what are the host elements that are involved to orientate the form
of the disease in a particular individual, and what regulates acute
exacerbation and remission phases in certain AIDs. Autoimmunity
may profoundly impact the continuous crosstalk held between the
central nervous system (CNS) and the immune system contributing
to the emergence of symptoms such as depression, mood and
anxiety disorders, or psychosis [2e4]. Some of these symptoms
have been reported to occur in neuropsychiatric systemic lupus
erythematosus (NPSLE).
In this complex picture, infections have been described as
decisive factors that not only trigger but also sustain and exacerbate
AIDs. Epidemiological studies show that the occurrence of SLE
differs according to countries, to areas of the same country and
between social groups. These differences suggest that besides ge-
netic susceptibility and intrinsic factors, environmental elements,
notably the infectious environment and the level of hygiene in
different world areas, are central in the development of this syn-
drome [5]. The composition of gut microbiota [6], which may
change as a function of diet modiﬁcation or following medication,
can also modulate and aggravate the course of SLE.
After summarizing the current consensus views of NPSLE
pathogenesis, this reviewwill focus on the possible ways infectious
agents may inﬂuence autoimmunity, the mechanisms of neuro-
inﬂammation and inﬂammation-induced behaviour, what they
imply in terms of blood-brain barrier (BBB) permeability, brain
cytokines and how, nowadays, we progress in our understanding of
neurodegeneration in NPSLE. A better understanding this “menage
a trois” (brain, immune system and infectious agents) in a disease
where there is still no speciﬁc treatment, is pivotal in our quest to
design novel therapeutic options based on personalised
approaches.2. Neuropsychiatric systemic lupus erythematosus
2.1. Symptomatology
SLE is a prototypic relapsing-remitting AID identiﬁed by
elevated titres of inﬂammatory mediators, hyper-activation ofperipheral B and T lymphocytes, production of potentially patho-
genic autoantibodies (autoAbs), clearance failure and tissue depo-
sition of immune complexes (ICs). These events precede
inﬂammatory conditions, which may cause end-organ damage [7].
SLE prevalence ﬂuctuates from 40 to 100 cases per 100,000 in-
dividuals, and even 40 to 200 among blacks in the US [8,9]. The
inﬂuence of hormones is central as 90% of patients are female and
the vast majority of cases occur during childbearing age. Linkage
between genetic and environmental factors (e.g. infections, pol-
lutants, UV radiation, stress) might underpin disease bursts and
justify the “waxing and waning” symptoms [10,11]. Although skin,
arthritis and renal lesions are the most common manifestations,
neurological and NP symptoms occur frequently [12]. When severe,
they substantially contribute to themorbidity andmortality rates of
patients [13].
NPSLE is a yet poorly understood disease that encompasses
some twenty central and peripheral symptoms (Table 1). CNS
symptoms largely predominate (93%) and may be diffuse or focal
[14]. The majority of NP manifestations appears early in the course
of SLE, most of them being not correlated with ﬂare or severity of
the disease. NPSLE is essentially clinically-deﬁned by physical ex-
amination, brain imaging, and serological, psychiatric and neuro-
psychological tests. However, despite improved imaging,
diagnosing NPSLE still remains a challenge [15e18]. The prevalence
of NP events ranges from 14% to 75% [19,20], reﬂecting important
differences in patient selection resulting from the absence of
consensus for diagnosing NPSLE. The genetics of NPSLE has rarely
been addressed. Of note, the gene TREX1 involved in apoptosis,
oxidative stress and several cerebral diseases has been linked to
NPSLE [21]. Larger genome-wide association studies of lupus pa-
tients are therefore eagerly awaited.2.2. Pathogenesis
The pathogenesis of NPSLE is particularly complex. The presence
of a chronic inﬂammatory state is commonly reported but no single
pathogenic dysfunction accounts for all NP symptoms, which result
from several pathogenic pathways including vascular and neuro-
inﬂammatory circuits (Fig. 1) [14,22,23].
Much data demonstrate that some NP symptoms are caused by
antiphospholipid Abs, which bind to clotting factors and endothe-
lial cells (ECs), inducing a pro-coagulant state. This mostly results in
focal manifestations that can be associated with structural brain
abnormalities at autopsy [24]. Both in murine models of lupus
[25e28] and in patients [29,30], diffuse manifestations were found
to result rather from inﬂammatory processes and toxicity mediated
by Abs binding neuronal cell surface receptors, such as neuronal
surface P antigen (NSPA) and N-methyl-D-aspartate receptor
Table 1
Neuropsychiatric syndromes described in lupus (ACRa classiﬁcation [145]) (adapted from Refs. [14,146]).
Central nervous system
Diffuse psychiatric/neuropsychological syndromes Focal neurological syndromes
Mood and anxiety disordersb Strokeb
Cognitive dysfunctionb Seizuresc
Headachesb Aseptic meningitis
Psychosisc Movement disorder
Depression Myelopathy
Acute confusional state Demyelinating syndrome
Peripheral nervous system
Autonomic neuropathyc
Cranial neuropathy
Polyneuropathy
Mononeuropathy (single/multiplex)
Myasthenia gravis
Plexopathy
Guillain-Barre syndrome
a Abbreviations: ACR, American College of Rheumatology.
b Mood and anxiety disorders, cognitive dysfunction, headaches and stroke are very common, but less speciﬁc
features
c psychosis, seizures and neuropathy present greater speciﬁcity for neurolupus.
H. Jeltsch-David, S. Muller / Journal of Autoimmunity 74 (2016) 13e26 15(NMDAR). The occurrence of autoAbs and proinﬂammatory cyto-
kines in the cerebrospinal ﬂuid (CSF), a liquid secreted within the
choroid plexus and diffusing into the cerebroventricular compart-
ments, could either result from leakages in the BBB (passiveFig. 1. Schematic view of pathogenic mechanisms of NPSLE. Genetic, neuroendocrine a
neuropsychiatric manifestations in lupus. Inﬂammatory mechanisms involve autoimmune
HPA axis, penetration of autoantibodies into the cerebral parenchyma and increased BBB per
diffuse manifestations encountered in neurolupus. Vascular mechanisms, mostly mediate
neuropsychiatric manifestations, and to a lesser extent, to diffuse neuropsychiatric events
generate immunological defects in susceptible subjects, inducing loss of tolerance towards n
b2-glycoprotein 1; BBB, blood-brain barrier; HPA, hypothalamic-pituitary axis; IFN, interfero
NPSLE, neuropsychiatric systemic lupus erythematosus; NR2, N-methyl-D-aspartate receptor
STAT4, signal transducer and activator of transcription 4; TNF, tumour necrosis factor; TREX
ultraviolet.transfer) or from intrathecal production [31]. Breach of the BBB is
critical for the access of Abs directed against NMDAR subunit 2
(anti-NR2, also known as anti-GluN2) to brain neurons [26,32,33].
The BBB can be permeabilised by SLE-linked factors (e.g. cytokines,nd environmental components participate to immune dysfunction and emergence of
damage, with upregulation of circulating proinﬂammatory cytokines, activation of the
meability, which is possibly linked to infection; these mechanisms mainly contribute to
d by antiphospholipid antibodies and immune complexes, contribute rather to focal
. In generic terms, neuropsychiatric manifestations occur after environmental factors
ative proteins. Infections play determinant roles in this scheme. Abbreviations: b2GP1,
n; IL, interleukin; IRF5, interferon regulatory factor 5; MMP, matrix metalloproteinase;
subtype 2; NSPA, neuronal surface P antigen; PAI-1, plasminogen activator inhibitor 1;
1, three prime repair exonuclease 1; TRPC, transient receptor potential canonical; UV,
H. Jeltsch-David, S. Muller / Journal of Autoimmunity 74 (2016) 13e2616autoAbs) and non-SLE factors (e.g. LPS, viral proteins, UV, stress,
hormones, smoking, certain addictive drugs) (Table 2) [34]. In
NPSLE, leakage in the BBB might be induced by the binding of
glutamate to NMDARs localised on brain ECs. NSPA participates to
NMDAR function, glutamatergic transmission and hippocampal
memory by moderating the detrimental action of anti-ribosomal P
protein Abs. Diffuse NPSLE symptomsmay arise after these autoAbs
gain access to cerebral areas co-expressing both NMDAR and NSPA.
Importantly, these two SLE-related autoAbs recognizing NSPA in-
ﬂuence glutamatergic transmission, albeit via distinctive processes
[35].
Increased intrathecal production of several cytokines (Fig. 1) by
neuronal and glial cells, presumably following intrathecal presence
of autoAbs, is also linked to NP manifestations in lupus [36e38]. As
suggested from in vitro studies, cytokines are produced after
binding of ICs to FcbRII on plasmacytoid dendritic cells (DCs; which
are major antigen-presenting cells of the immune system) and
stimulation of TLR7. This mechanism is substantiated by the pres-
ence, in the CSF of NPSLE patients, of degraded neuronal and glial
material (potential antigens source), and increased matrix
metalloproteinase-9 levels [39], which augment BBB permeability,
thus providing intrathecal access to circulating autoAbs [22,40]. It is
worth mentioning that high levels of oxidative and nitrosative
stress (O&NS) are signiﬁcantly associated to neurodegeneration
and might be an important component of NPSLE [41]. Whether
neurological dysfunction progresses independently, results from
systemic disorder, or both, remains unclear. In fact, CNS dysfunction
and NP manifestations could be part of existing disease or they
could be consecutive to treatment, infection, and metabolic
dysfunctions.
2.3. Sickness behaviour
Depression, fatigue, anhedonia and defects in cognition are
frequently noted in clinical conditions where inﬂammation is al-
ways reported, which could then be considered as a pivotal
contributor to the expression of such symptoms [42,43]. In rodents,
alteration in cognition, emotionality and sleep-wake cycle is
detected after peripheral immune activation [44]. These modiﬁca-
tions coexisting with activation of the peripheral immune system
are known as “sickness behaviour” [45,46], which is well-
documented in SLE and in spontaneous murine models, notablyTable 2
Examples of factors modulating the BBB'sa permeability (data adapted from Ref. [34]).
Conditions Substances Action
Infections LPS ECs activation
P-glycoprotein regulation
Cytokines secretion
Viral proteins (e.g. HIV) Tight junction dysfunction
Perivascular macrophages and microg
Inﬂammation Cytokines (e.g. TNFa, IL-1b, IL-
6, Type 1 IFN)
ECs activation
Tight junction dysfunction
Circulating Abs (e.g. anti-NR2
Abs,
anti-P autoAbs)
Recognition of neuronal cell surface a
mechanisms (when Mg2þ is removed
involves NMDAR activation
Stress, stroke Glutamate Vasodilatation
ECs activation
Hormonal
dysfunctions
Œstrogens (e.g. 17b-œstradiol) Inhibition of MMP2 and MMP9
Glucocorticoids (e.g.
dexamethasone)
VEGF and angiopoietin regulation
Addictive
agents
Tobacco (e.g. nicotine) Tight junction modulation
Coffee (e.g. caffeine) Action on junctional proteins by neur
Alcohol (e.g. ethanol) Choroid plexus dysfunction
a Abbreviations: Ab, antibody; BBB, blood-brain barrier; ECs: endothelial cells; HIV, hu
magnesium; MMP, matrix metalloprotease; NMDAR: N-methyl-D-aspartate receptor; NR2
VEGF, vascular endothelial growth factor.in MRL/lpr lupus-prone mice. As compared to MRLþ/þ mice coun-
terparts, MRL/lpr mice display deﬁcient cognitive performances in
spontaneous alternation (Fig. 2; Jeltsch-David and Muller, unpub-
lished observations) and water maze tasks, suggestive of hippo-
campal dysfunction and consequences on the neural processing of
learning and memory [47,48]. It is worth noting that SLE patients
displaying cognitive difﬁculties may also present structural hip-
pocampal anomalies [46,49].
3. Immunity, infection and central inﬂammation
3.1. The immune system: its basics
The immune system includes the innate and the adaptive sys-
tems, and is composed by cells adjusted to protect the organism
against foreign agents, while being nonreactive towards self [50].
The body responds to pathogenic exogenous and endogenous sig-
nals with comparable reactions via sentinel cells (e.g. monocytes,
macrophages, DCs, microglia), which initiate an inﬂammatory
response followed by a “mirrored” immune reactionwithin the CNS
(neuroinﬂammation), possibly resulting in behavioural symptoms.
Pathogenic agents exhibit pathogen-associated molecular patterns
(PAMPs) that activate pattern-recognition receptors (PRRs). The
latter recognise PAMPs as non-self-molecules and damage-
associated molecular patterns (DAMPs) as self-molecules. Both
give rise to innate response, one to eradicate invading elements and
the other to eliminate injured tissue. Among the most widely
studied PRRs are TLRs, which, for some, recognise extracellular
pathogens (primarily bacteria) and for others, present within
endosomes and lysosomes, interact with intracellular pathogens
(Table 3). The activation of TLRs promotes inﬂammatory responses
by generating intracellular signalling cascades via two main path-
ways, namely myeloid differentiation primary response 88
(MyD88) and Tir-domain-containing adaptor inducing interferon-b
(TRIF) pathways. Almost all TLRs combine MyD88 inaugurating a
series of events to ﬁnally initiate NFKB, whose translocation directly
stimulates gene transcription of TNFa, IL-1b and IFNg. Only TLR3
strictly associates with TRIF signalling to induce IFNa and IFNb. TRIF
pathway seems to mainly play a role against viral infections, and
Myd88 against bacterial ones. Concerning Nod-like receptors, they
act similarly as TLRs by initiating inﬂammatory reactions after
recognition of bacteria's peptidoglycans.lia activation
ntigens, and enhancement of glutamatergic transmission through two different
and in the presence of Mg2þ, respectively); the mechanism mediated by NSPA
otoxins and other agents
man deﬁciency virus; IFN, interferon; IL, interleukin; LPS, lipopolysaccharide; Mg2þ:
: NMDAR subtype 2; NSPA: neuronal surface P antigen; TNF, tumour necrosis factor;
Fig. 2. Behavioural deﬁcits in MRL/lpr mice as compared to control MRLþ/þ mice. aj As compared to age-matched counterparts, 17 week-old MRL/lpr mice display T-maze
alternation deﬁcit (t28 ¼ 4.573, p < 0.0001). bj The maze included three Plexiglas arms (24  17  5 cm). Mice were tested over 5 days; a daily session consists of trial#1 (5 s in the
start position, and entry into the unblocked arm), 20-s inter-trial period (restraining in the arm), and trial#2 where both arms are open and the mouse is expected to choose the
unvisited arm. cj Concerning circadian activity, MRL/lpr mice showed, at the same age, a marked hyperactivity as compared to MRLþ/þ control mice (“Substrain”: F(1,42) ¼ 4.759,
p ¼ 0.034, “Phase”: F(1,42) ¼ 33.96, p < 0.0001, “Substrain”  “Phase”: F(1,42) ¼ 5.786, p ¼ 0.021), particularly during the diurnal phase of the cycle (p < 0.05). Circadian activity was
continuously recorded over one week using infrared captors mounted on the top of the cages. dj Finally, a signiﬁcant reduction of brain weight was noticed in 17 week-old diseased
MRL/lpr mice (t21 ¼ 2.188, p ¼ 0.040), observation that is in line with the cerebral atrophy classically reported in some NPSLE patients. ej Furthermore, we found a signiﬁcant
negative correlation (r11 ¼ 0.654; Pearson's test) between brain's weight and diurnal activity in MRL/lpr mice (p ¼ 0.028) (Jeltsch-David and Muller, unpublished observations).
Statistics: Alternation scores and brain's weight data were analysed with unpaired t-test (two-tailed). Circadian activity was analysed with a two-way ANOVA (“Substrain” and
“Phase” as between factors) with Bonferroni post-hoc tests. Signiﬁcance was deﬁned as p < 0.05: *p < 0.05, ****p < 0.0001, ns, not signiﬁcant. Errors bars are mean standard
deviation. Sample size is indicated as n. The experimental protocol and animal care were carried out in strict accordance with EU regulations (European Community Council
Directive 2013-118 of February 1, 2013) and with the recommendations of the French national chart for ethics of animal experiments (articles R 214-87 to 126 of the “Code rural et
de la pe^che maritime”; authorization no. 04436.02). The protocol was also approved by the local committee on the ethics of animal experiments (CEEA 35). All efforts were made to
minimize animal suffering and to respect the concept of the 3Rs (Reduce, Reﬁne, Replace).
Table 3
Central receptors and molecules of innate immunity and their effects (data adapted from Ref. [4]).
PRRsa Neuron Microglia Astrocyte Infectious agent Signalling pathways Secreted cytokines
TLR1  þ  Bacteria Myd88 TNFa,IL-1b, IFNg
TLR2  þ þ Bacteria Myd88 TNFa,IL-1b, IFNg
TLR3 þ þ þ Bacteria-virus TRIF IFNa,IFNb,TNFa,IL-6
TLR4  þ  Bacteria-virus Myd88 TNFa,IL-1b,IFNg
TLR5  þ  Bacteria Myd88 TNFa,IL-1b,IFNg
TLR6  þ  Bacteria-fungi Myd88 TNFa,IL-1b,IFNg
TLR7 þ þ  Bacteria-virus Myd88 IFNa,IFNb,TNFa,IL-1b
TLR8 þ þ  Bacteria-virus Myd88 TNFa,IL-1b,IFNg
TLR9 þ þ þ Bacteria-virus Myd88 IFNa,IFNb,TNFa,IL-1b
Nod2 þ þ Bacteria RIPK or RICK TNFa,IL-1b,IL-6
TNFaR þ low low / / /
IL-1R þ þ þ / / /
IL-6R low low low / / /
IFNaR þ þ þ / / /
IFNgR þ þ þ / / /
a Abbreviations: IFN, interferon; IL, interleukin; MyD88, myeloid differentiation primary response 88; Nod, nucleotide-binding oligomerization domain 2; PRR, pattern
recognition receptor; R, receptor; RIPK, receptor-interacting serine-threonine kinase 2, aka RICK; TLR, Toll-like receptor; TNF, tumour necrosis factor; TRIF, TIR (Toll/inter-
leukine-1 receptor-like) domain-containing adaptor-inducing interferon-b.
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Inﬂammation is not synonymous to infection; its understanding
requires distinction between innate and adaptive immune re-
actions, which are functionally intertwined [51]. Inﬂammation is
the innate system's response to ﬁght infection. It is boosted by
cytokines released by sentinel cells. This secretion and the resulting
activation of NFKB upregulate cytokines and O&NS pathways,
which in turn upregulate NFKB, perpetuating chronic inﬂammation
process and immune activation via TLRs. As aggravating factors,
O&NS may generate redox-derived DAMPs, further leading to
activation of NFKB and cytokines. Thus, chronic inﬂammation and
immune activation can be prolonged and even heighten by
engagement of TLRs and DAMPs [52].
Bacterial, viral, parasitic and fungal infectious agents are able to
trigger autoimmunity (the pathogen must be present to initiate the
disease), activate autoimmunity in genetically-predisposed sub-
jects (the pathogen is not essential but its presence precipitates or
aggravates the pathology), or even they can impede autoimmunity
[53]. Hypotheses linking infection and autoimmunity have been
formulated, and ﬁve major mechanistic lines have emerged. They
include molecular mimicry, ‘epitope spreading’ [i.e. diversiﬁcation
of the immune response (e.g. B- and T-cells, Abs) following initia-
tion of immunity to a single or few foreign or self-components],
bystander activation, polyclonal activation of lymphocytes, and a
mechanism in which bacteria and viruses produce super-antigens
(Table 4) [54]. Viruses may also activate intracellular TLRs
through intracellular signalling pathways, inducing expression of
type 1 IFN genes, leading to the typical ‘interferon signature’
described in lupus [55].
Viral or bacterial infections take part in lupus disease develop-
ment by inducing cellular debris, which activate B-cells, or pro-
moting autoAbs production. Thus, infections by cytomegalovirus,
Parvovirus B19 and Epstein-Barr virus (EBV) are frequently cited in
the production of favourable immune conditions allowing auto-
immune phenomena, or as breakers of immune tolerance to self-
molecules. Molecular mimicry could be one mechanism respon-
sible for the generation of lupus autoAbs and data obtained with
EBV are particularly relevant [56]. Interestingly, an association be-
tween high titres of EBV Abs and skin and joint symptoms, but not
with NP manifestations, have been found in lupus patients [57].
3.3. At the CNS level: cells in the brain parenchyma
In the CNS, the main cell types are neurons and glial cells
(monocyte origin), which are further distinguished between
microglial and macroglial cells (e.g. astrocytes, oligodendrocytes).
Astrocytes are star-shaped glial cells providing mechanical andTable 4
Main mechanisms used by pathogens for the activation of autoreactive T and B-cells (ad
Mechanism Actions
Molecular mimicry Microbial pathogens displaying structural resemblance w
Epitope spreading Microorganisms speciﬁc to TH1 cellsa are activated, leadi
self-reactive TH1 cells
Bystander activation The production of cytokines is ampliﬁed, which induces
Polyclonal activation Lymphotropic viruses stimulate lymphocytes, resulting i
Bacterial and viral super-
antigens
Microorganisms produce proteins, which through bindin
Alteration of apoptosis Non-ingested nuclear elements supply survival cues for
features
Deﬁcits of the immunity Defect of the complement leads to decreased and inadeq
IFN signature Activation of intracellular receptors (TLRs) via intracellu
a Abbreviations: Abs, antibodies; APCs: antigen-presenting cell; ICs: immune comple
helper cell; TLRs, Toll-like receptors; TCR, T-cell receptor.metabolic support for neurons, thereby regulating the external
chemical environment by removing excess ions and recycling
neurotransmitters. They respond to pathological changes with
hypertrophy and hyperplasia, and are also essential for the integrity
of the BBB, acting as ﬁltres. Withmicroglial cells, they are the brain-
resident macrophages, being actively involved in immune defence
[58]. They regulate and limit inﬂammatory processes [59] through
different mechanisms [e.g. production of anti-inﬂammatory mol-
ecules, expression of receptors (e.g. PRRs, receptors for cytokines
and growth factors that are released by damaged neurons, re-
ceptors critical for antigen presentation)]. Microglial cells migrate
into CNS during development, where they continue to expand
speciﬁcally after trauma (being able to be directly activated by
PAMPS and DAMPS) in which case they react by displaying
morphological and functional changes (Fig. 3) with central proin-
ﬂammatory cytokine expression (Table 3). Microglial cells are
critical in both neuronal protection and pathology [60]. They
notably produce neurotrophic substances crucial for cellular repair
and recruitment of immune cells capable of eliminating pathogens
or cell debris from the CNS. Increased microglial activation is
related to both exaggerate production of proinﬂammatory mole-
cules and neurodegenerative process [61]. According to the classi-
ﬁcation of microglia, M1-polarised microglia are prone to produce
proinﬂammatory cytokines, reactive oxygen species (ROS) and ni-
tric oxide (NO), whereas M2 cells rather inhibit inﬂammation and
reinstate homeostasis [62]. Microglia would be polarised to M1
type in high-anxiety inbred mice, especially after a peripheral
innate immune challenge, revealing thus potential molecular
mechanisms of how anxiety might regulate microglial activation
and polarization [63]. In SLE, even if reactive microglia has been
observed in patients suffering from CNS troubles [64], the role of
microglia remains to be deeply characterised. In lupus-prone mice,
microglia activation and cytoplasm condensation suggest meta-
bolic perturbations, which lead to dysfunction as well as early
neuronal death [65]. In this complex scenario, infections seem to
play a major, possibly triggering, role. Microglia is also an essential
element of a competent BBB, which permit crosstalk between pe-
ripheral and CNS immune activities [66]. Centrally, neurons and
astrocytes are generally not activated by PAMPs. The lack of most of
the bacterial TLRs on neurons suggests that the consequences of a
bacterial infection on behaviour are secondary to activation of other
CNS cells, primary microglia (Table 3) [4].
4. Inﬂammation-induced behaviour
Circulating cytokines and proinﬂammatory molecules affect the
CNS through neural and humoral circuits [67]; the neural circuit is
related to afferent nerves, while the humoral pathway is mostlyapted from Refs. [54,147]).
ith self-peptides activate autoreactive T and B-cells
ng to release of self-peptides, which are further engulfed by APCs and exposed to
expansion of autoreactive T-cells at an inﬂammatory site
n increased Abs production and ICs in the circulation
g to TCR and MHCII, activate numerous T-cells of different antigenic speciﬁcity
autoreactive B-cells, this resulting to Abs production against exposed nuclear
uate clearance of infectious substances
lar pathways leads to expression of type 1 IFN genes
xes; IFN, interferon; MHCII: major histocompatibility complex Classe II; TH cell: T
Fig. 3. Immune proﬁle, activation and polarization of microglial cells Microglial cells express MHC molecules and macrophage markers. In the central nervous system, these
cells are sentinels and preserve homeostasis. When pathological changes occur, resting microglial retract their long cellular processes, thus developing an amoeboid appearance. In
the presence of LPS or IFNg, microglial cells differentiate to M1 phenotype and secrete proinﬂammatory factors. In the presence of IL-4, IL-13 or CCL2, they polarise to M2
phenotype, which inhibits M1 microglia functions via IL-10 secretion. It is likely that the balance between exacerbation and recovery of central inﬂammation is highly regulated by
microglia M1/M2 polarization. Abbreviations: CCL2, monocyte chemoattractant protein 1; CD, cluster of differentiation; CSF1R, colony-stimulating factor 1 receptor; CX3CR1, CX3
chemokine receptor 1 (also known as fractalkine receptor); DAMP, damage-associated molecular pattern; IFN, interferon; IL, interleukin; LPS, lipopolysaccharide; MHC, major
histocompatibility complex; NO, nitric oxide; PAMP, pathogen-associated molecular pattern; ROS: reactive oxygen species. Figure realised thanks to material provided by Servier
Medical Art (www.servier.fr) under the CC 3.0 FR license.
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blood to the CNS, and then protects the brain from blood-borne
pathogens [68].
4.1. BBB: its compromise in neuroinﬂammation
The BBB is a selectively permeable barrier formed by astrocytes
and capillary endothelial cells connected by tight junctions, which
restricts passage of small molecules into the brain. Part of the
innate immune defence against pathogens entering the CNS is
achieved by the BBB. When systemic inﬂammation occurs, as in
SLE-related neuropathology, the permeability of the BBB increases
[68,69]. Different cases of blood-to-brain signalling have been re-
ported [70]. For example, peripheral inﬂammation induced by LPS
directly provokes release of proinﬂammatory factors, activation of
brain ECs, which further leads to upregulation of cell adhesion
molecules, destabilization of tight junctions, thereby weakening
BBB integrity [71]. After sepsis induction in mice, the BBB becomes
rapidly leaky (24 h) with dramatic neuronal degeneration [72].
Following peripheral LPS challenge, brain region-speciﬁc upregu-
lation of gene coding for several cytokines (IL-1b, IL-6), glial
ﬁbrillary acidic protein and immune cell markers are also observed,
demonstrating that cortical inﬂammation and glial stimulation
arise in the context of peripheral inﬂammation [73,74]. In mice,
even a single injection of a low LPS dose (5 mg/kg) generates long-
lasting affective modiﬁcations as diminution of exploratory
ambulation and increase in depressive- and anxiety-like behav-
iours [75]. Similarly, in rats, LPS administered once is followed by
prolonged neuroinﬂammation [76].
4.2. Cytokines and NP manifestations
Abnormal levels of circulating cytokines evidence chronic
inﬂammation and immune activation, and is commonly observed
in lupus [77]. In human and murine lupus, cytokines play an active
role in the pathophysiology of the disease, contributing to the
production of pathogenic autoAbs and to depression and sickness
behaviour [78]. Furthermore, via their action on TLRs, cytokines arethought to impair hippocampal neurogenesis [79], which is an
important mechanism in depression [80].
Cytokines acting on the brain proceed either peripherally or
centrally [47]. From the periphery, cytokines enter the brain by
different ways, including (i) cytokine passage through leaky BBB
regions, (ii) active transport via transport molecules, (iii) activation
of ECs and perivascular macrophages, and (iv) binding to cytokine
receptors present on afferent ﬁbres (the vagus nerve) [81]. At the
BBB interface, NFKB is pivotal to transmit signals. In rodent, it was
demonstrated that inhibiting central NFKB activity prevents acti-
vation of c-fos in different cerebral areas and accelerates recovery
from LPS- and IL-1b-induced sickness [82,83].
Cytokines produced centrally by astrocytes and microglia
directly contribute to vasculopathy of focal ischemic and haemor-
rhagic brain disease. In lupus, several reports demonstrated that
deregulated secretion of cytokines happens within the CNS, as IL-1,
IL-6, IL-8, IFNa, APRIL or BAFF, are found in the CSF of NPSLE pa-
tients [84,85]. IL-6 is commonly associated with SLE, inﬂammatory
and neurological states, cerebrovascular disease, as well as
depressive events [86]. Thus, activation of IL-6 and NFKB pathway is
linked to deregulated sleep in depressed patients [87]. The BBB
integrity and intrathecal IgG synthesis levels are classically evalu-
ated by IgG index and Q-albumin test, respectively [70]. As such, the
fact that IL-6 CSF levels are associated with IgG index implies that
increased intrathecal IL-6 may enhance B-cell responses within the
CNS [88]. In addition to IL-6, IFNa is another cytokine that is
associated with several NP symptoms in SLE and whose secretion is
stimulated by ICs resulting from the binding of CSF autoAbs to
antigens released by neurocytotoxic Abs [89].
Cytokine inducers (e.g. LPS, vaccination) can also cause behav-
ioural manifestations overlapping those reported in depression.
Then, LPS-administered healthy volunteers display acute anxiety
and depressive behaviour and, as well, injection of a Salmonella
typhi vaccine to healthy persons results in fatigue, depression,
cognitive difﬁculty and psychomotor slowing [90,91]. The complex
molecular and mechanistic interplay between neuroinﬂammation
and infection in a context of autoimmunity has immediate conse-
quences in clinical terms.
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Under systemic inﬂammatory conditions, as those occurring
during NPSLE, several mechanisms may activate neuro-
inﬂammation and neurodegeneration. Thus, due to increased
permeability of the BBB, peripheral immune cells and inﬂamma-
tory factors penetrate in the CNS where they provoke several
reactive phenomena, including (i) astrogliosis (also known as
reactive astrocytosis), which is an aberrant augmentation of the
astrocytes density inducing diminution of synaptic maintenance,
(ii) damages of myelin sheaths, which cause demyelination andFig. 4. Cerebral milieu and BBB modiﬁcations following systemic inﬂammation in NP
dendrocytes) and synapses. Astrocytes combine with blood vessels and constitute the BB
inﬂammation and autoimmunity features appear: peripheral immune cells and proinﬂamm
and ROS injure myelin sheaths, leading to demyelination and axonal degeneration. Densi
ﬂammatory phenotype with diminution of phagocytic function and release of neurotoxic
function by several ways. aj When infection occurs, pathogens (e.g. LPS) bind TLR4s (NFKB
phages at circumventricular zones. bj Cytokines secreted systemically in response to LPS act
Cytokines may also cross the BBB using speciﬁc transporters, and then activate immune cell
transported into the brain by receptor-mediated endocytosis. In short: (I) Firstly, presence
Secondly, cascade of endothelial inﬂammatory events (production and release of NO, ROS,
cascades (macrophages inﬁltration, astrocytes and microglia activation; unregulated inﬂam
BBB, blood-brain barrier; CD, cluster of differentiation; CNS, central nervous system; ECs, e
nitric oxide; NPSLE, neuropsychiatric systemic lupus erythematosus; ROS, reactive oxygen s
material provided by Servier Medical Art (www.servier.fr) under the CC 3.0 FR license.axonal degeneration, and (iii) microgliosis, which usually involves
hypertrophy and proliferation, and generates a proinﬂammatory
phenotype of microglial cells with diminution of phagocytic and
tissue homeostasis function (Fig. 4).
Cerebral perturbations can be direct effects of soluble factors or
may be indirectly linked to reactive astrocytic and microglial re-
sponses. Data demonstrated that LPS activates microglial cells and
contributes to cognitive dysfunction via an IL-1-dependent process;
thus, the blockage of IL-1 signalling weakens the LPS inﬂammatory
cascade, thereby attenuating microglial activation and hampering
behavioural abnormalities [92].SLE. Neurons are connected by axons (isolated by myelin sheaths provided by oligo-
B. Microglia survey the CNS, eliminating apoptotic cells. When inﬂammation, neuro-
atory mediators target ECs and cross the BBB, exerting direct and indirect damages. NO
ty of astrocytes increases, leading to damage of BBB. Lastly, microglia adopts proin-
mediators generating ROS [101]. Circulating inﬂammatory factors may affect cerebral
activation) on ECs, inducing leakage of the BBB and activation of perivascular macro-
on cytokine receptors present on ECs, thus altering the architecture of tight junctions. cj
s in situ, further amplifying BBB dysfunction. djCirculating Abs recognizing NMDAR are
of proinﬂammatory circulating factors (e.g. microbial substances, Abs, cytokines); (II)
cytokines, upregulation of adhesion molecules); (III) Lastly, parenchyma inﬂammatory
mation leading to neuronal injury and brain disease). Abbreviations: Abs, antibodies;
ndothelial cells; LPS, lipopolysaccharide; NMDAR, N-methyl-D-aspartate receptor; NO,
pecies; TLR4, Toll-like receptor 4. Figure adapted from Ref. [101] and realised thanks to
H. Jeltsch-David, S. Muller / Journal of Autoimmunity 74 (2016) 13e26 21Immune control of the CNS and regulation of neuro-
inﬂammation are provided by brain microglia and peripheral im-
mune cells [93e95]. The total elimination of infectious agents
during cerebral infection generally entails irreversible cerebral
tissue shrinkage, which however may be counteracted by processes
of pathogen tolerance, as exempliﬁed with HSV [96].
5.1. Caspases in neurodegeneration and inﬂammation
An important trigger for neurodegenerative processes is
apoptosis. Under physiological conditions, apoptosis constantly
occurs and cell fragments are removed without release of inﬂam-
matory mediators [97]. During systemic inﬂammation, such as
lupus-related neuropathology, apoptosis of stressed cells but also
pyroptosis, which is a form of programmed cellular death linked to
antimicrobial response, might further exacerbate the underlying
pathology [98]. Directly and indirectly, apoptosis stimulates cas-
pases, which are effectors of apoptosis but are also important for
initiating innate immune response through inﬂammasome [99], a
multiprotein complex expressed in myeloid cells, thereby consti-
tuting essential element of the innate immune system, which
cleaves pro-interleukin into proinﬂammatory cytokines (Il-1b, IL-
18) and induces pyroptosis. Nowadays, data extend the role of
caspases relating neuroinﬂammation to neurodegenerative pro-
cesses [100,101]. Caspases activation has also a crucial role in lupus,
as they can cleave self-proteins leading to fragments (some of
which encompass apoptosis-speciﬁc post-translational modiﬁca-
tions) that can be potent immunogens [102].
5.2. Immune cells, AutoAbs, and neuroimmunology
Proinﬂammatory cytokines, reactive oxygen species (ROS) and
activated immune cells directly trigger apoptosis of central neurons
[103]. Similarly, anti-brain Abs, such as anti-NMDAR Abs, can drive
cerebral pathology further affecting behaviour and cognition, as
described in SLE [104,105].
In NPSLE patients, the pathogenicity of CSF IgG Abs to NR2
subunit has been published both in vitro and in vivo [26,33]. Patient-
derived NMDAR Abs mediate persistent cognitive impairment as
well as neuronal damage the hippocampus, which in one cerebral
area crucially implicated in learning and memory process, of mice
[27]. Structural abnormalities and hypermetabolism have also been
similarly evidenced in the hippocampus of NPSLE patients [49,105].
All these ﬁndings, and others published more recently in NPSLE
patients, suggest that NMDAR Abs are directly implicated in neu-
rodegeneration [34,105]. Recently, authors proposed that anti-NR2
Abs and NFKB activation may generate NPSLE pathogenesis [28]. An
observation that may be highly relevant concerning reversibility of
symptoms is that depending on their concentration, NMDAR Abs
may either induce neuronal perturbation by transitory increment
of excitatory postsynaptic potentials, or provoke neuronal death
[101,106].
Synaptic autoimmunity is currently an exciting burgeoning ﬁeld
of research. The identiﬁcation of neurological syndromes, particu-
larly encephalitis, associated with autoAbs reacting with extracel-
lular epitopes of synaptic receptors and constituents of trans-
synaptic protein complexes [107,108] displays determinant inter-
est, extending and re-questioning classical concepts of neurosci-
ence, neurology and psychiatry [109,110]. Targeted antigens that
include NMDAR, alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPAR), inhibitory gamma-
aminobutyric acid B receptor (GABABR) or the glycine receptor
(GlyR) are all essential actors of synaptic transmission, plasticity
and nerve excitability. Other autoantigens are also implicated in
mechanisms such as the secreted neuronal protein leucine-richglioma-inactivated-1 (LGl1), contactin-associated protein-like 2
(Caspr2) and the intracellular enzyme glutamate decarboxylase
(GAD). Clinical expression of these immune reactions is described
in Table 5. In the past, these syndromes were considered as idio-
pathic or of unknown viral cause, and were designated with
descriptive terms (i.e. dyskinetic encephalitis lethargica) [111]. The
most extensively described neuronal cell surface Abs are here again
NMDAR-Abs of individuals suffering from anti-NMDAR encephali-
tis. At the beginning, and due to its high relation with teratoma,
anti-NMDAR encephalitis was categorised as a paraneoplastic
syndrome [112]. However, a growing set of clinical evidence pro-
poses that it may be rather considered as a neuroimmune disorder,
where Abs are expressed following several signals (infection,
tumour) and bind to synaptic proteins and NMDAR [113]. These Abs
recognise NR1 subunit of the NMDAR, cross-react and internalise
the receptor, thus decreasing the receptor density, and impairing
neuronal functioning [109,114]. Autophagy may be another mech-
anism of action of these autoAbs; in this case, the process of
degradation of NMDAR is comparable to that described in the case
of acetylcholine receptors inmyasthenia gravis [115]. It is important
not to confuse NMDAR-Abs, which are greatly speciﬁc for anti-
NMDAR encephalitis, with NMDAR autoAbs detected in SLE in-
dividuals that recognise a linear epitope of the NR2A and B subunits
of the NMDAR [109].
6. Implication for the treatment
For the last few decades, SLE patients are living signiﬁcantly
longer in developing countries thanks to both earlier diagnosis and
administration of high doses of glucocorticoids or other cytotoxic/
immunosuppressive agents [116]. However, although such drastic
treatments have lowered the mortality rate, we noticed that drug
side effects, especially infections (e.g. bacterial sepsis, mycobacte-
rial infection recrudescence, fungal and viral infection and/or
reactivation, in some cases with dramatic consequences such as
virus-induced malignancies) have been described in lupus patients
[117e119]. This increased risk is linked to the disease itself (Table 6),
but also to immunosuppressive treatment the patients receive to
reduce some of their inﬂammatory symptoms and pain. Potentially,
immunosuppressive therapy could also affect the ability of treated
patients to behave appropriately to preventive vaccination. At least
in part, this legitimate concern can be discarded, as there is no
objective evidence, in large case reports, that vaccination causes
lupus ﬂares when killed vaccines are used [e.g. inﬂuenza, pneu-
mococcal and hepatitis B (HBV) vaccines]. In general, however, live
vaccines (e.g. varicella, measles, and rubella) are not recommended
due to the potentiated infection risk from the vaccine, and should
be preferably replaced by killed vaccines since the latter are avail-
able. It is also recommended that patients with lupus get vaccina-
tion outside active episodes of their disease and following careful
consideration of their individual medication usage [120e122].
Some cases of ﬂares have been described after vaccination against
HBV, papillomavirus and norovirus. In summary, however, only few
vaccines are unsafe in lupus patients. When carefully managed,
vaccination is even particularly encouraged as it may signiﬁcantly
decrease the mortality in SLE population.
Nowadays, as infections are the main causes of morbidity and
mortality in SLE [123e125], management and prevention of in-
fections arise of greater importance [126]. In addition to adapted
strategies of vaccination described above, there is an urgent need to
replace immunosuppressive drugs by molecules that will modulate
the autoimmune response without affecting the whole immune
system [127,128]. This challenge appears set to be successful with
the P140 synthetic peptide (also known as Lupuzor™), which cor-
responds to a sequence of the U1-70K spliceosomal protein. This
Table 5
Encephalitis related to major Absa to neuronal cell surface antigens and their clinical characteristics (adapted from Refs. [3,107,109,148e151]).
NMDAR AMPAR GABABR GlyR LGl1 Caspr2
Gender Female (80%) Female (90%) Female (50%) Male (60%) Male (65%) Male (85%)
Age
(median)
21 yrs 60 yrs 62 yrs 46 yrs 60 yrs 60 yrs
Symptoms Seizures; psychosis; abnormal
movements; language and
memory dysfunction; defect of
consciousness;
hypoventilation; breathing and
autonomic instability
Seizures; agitation;
confusion; disorientation;
mood disorder; irritability;
short-term memory
dysfunction; psychosis;
limbic encephalitis
Prominent seizures; memory
dysfunction; confusion;
disorientation; hallucination;
mood disorder; ataxia;
irritability; psychosis; limbic
encephalitis
Progressive
encephalo-
myelitis with
rigidity and
myoclonus;
Stiffman
syndrome
Tonic-myoclonic
seizures; limbic
encephalitis;
amnesia; apathy;
irritability;
confusion;
disorientation
Encephalitis,
neuromyotonia, or both
(Morvan syndrome);
seizures; confusion;
amnesia; insomnia;
weight loss
MRI Transient increase of FLAIR
signal in the cerebellar cortex
or in medial temporal lobes;
intracranial hypertension;
demyelination
Increase of FLAIR signal in
medial temporal lobes
Increase of FLAIR signal in
medial temporal lobes
Normal Increase of FLAIR
signal in medial
temporal lobes
Increase of FLAIR signal in
medial temporal lobes
when encephalitis;
spontaneous muscular
hyperactivity (EMG)
when neuromyotonia
Tumour Ovarian teratoma in most cases Small cell lung carcinoma,
thymoma, breast cancer
Small cell lung carcinoma Thymoma;
Hodgkin
lymphoma
Thymoma (rare) Limited data: probably
thymoma
CSF Lymphocytosis; increased
protein level; CSF-speciﬁc
oligoclonal bands; frequent
intrathecal Abs synthesis
Lymphocytosis; increased
protein level; CSF-speciﬁc
oligoclonal bands; frequent
intrathecal Abs synthesis
Lymphocytosis; increased
protein level; CSF-speciﬁc
oligoclonal bands; constant
intrathecal Abs synthesis
Usually normal;
occasional mild
lymphocytosis
Infrequent
intrathecal Abs
synthesis
Limited data concerning
intrathecal Abs synthesis
Other Abs ~10% (ANA, TPO) ~60% (ANA, TPO, GAD65,
VGCC, SOX1, cardiolipin)
~50% (VGCC, GAD65, TPO,
SOX1)
Unknown ~10% (ANA, TPO,
GAD65)
~20% MuSK; AChR, GAD65
Outcomes Good when immunotherapy;
possible cognitive sequelae
Tendency to relapse Good, with rare relapses Good Good, or mild
sequelae
Limited data
a Abbreviations: Abs, antibodies; AChR, acetylcholine receptor; AMPAR, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; ANA, antinuclear Ab;
Caspr2, contactin-associated protein-like 2; CSF, cerebrospinal ﬂuid; EMG, electromyogram; FLAIR, ﬂuid-attenuated inversion recovery; GABABR, gamma-aminobutyric acid B
receptor; GAD65, glutamic acid decarboxylase 65; GlyR, glycine receptor; LGl1, leucine-rich glioma-inactivated 1; MRI, magnetic resonance imaging; MuSK, muscle-speciﬁc
kinase; NMDAR, N-methyl-D-aspartate receptor; SOX1, sex determining region Y-box 1; TPO, thyroid peroxidase; VGCC, voltage-gated calcium channel; yrs, years.
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residue at the position 140, and only the modiﬁed peptide displays
protective properties in a murine model of lupus [129]. In patients,
P140/Lupuzor™ is well tolerated [130], non immunogenic [129],
and a phase III-clinical study is currently in progress. In MRL/lpr
lupus-prone mice, P140 binds HSPA8/HSC70 chaperone protein,
decreases its expression and reduces autophagic ﬂux in B lym-
phocytes of peptide-treated mice [131]. P140 interferes with
chaperone-mediated autophagy (CMA) [132]. It induces lower
expression of MHC-II molecules and alteration of peptides pre-
sentation to autoreactive T-cells, leading to a reduction of T and B-
cells activation and a drop of potentially pathogenic autoAbs pro-
duction. This process is without effect on the resistance of mice to
infection by Flu virus, meaning that after P140 treatment, the
overall immune system remains intact. Based on this unique se-
lective inhibitory effect of P140 peptide on CMA, we anticipate that
P140/Lupuzor may be efﬁcient in several other pathological con-
ditions in which activity of CMA is abnormally raised as is the case,
particularly, in several neuroinﬂammatory diseases [132,133].Table 6
Susceptibility factors for infections in lupus patients.
Genetically predisposing factors Risk factors
Genetic complement deﬁciency Leucopenia
MBLa deﬁciency
CRP deﬁciency
Functional hyposple
Hypogammaglobulin
Complement deﬁcie
Corticosteroid use (p
Immunosuppressive
Biologics (e.g., rituxi
High-dose chemothe
Splenectomy
a Abbreviations: CRP, C reactive protein; MBL, mannose-binding lectin.
b The risk for developing infection is dose-dependent.7. Outstanding questions and future research
Research is still at the beginning concerning how infectious
pathogens are able to trigger, sustain, or exacerbate neuro-
inﬂammation and neurodegeneration, as well as concerning the
precise role of T-cells in CNS homeostasis. Are these cells only
pathogenic in being involved in CNS injury following infection and
neurodegeneration? Or could certain T-cells subsets also be
implicated in limiting neuroinﬂammation? A breakthrough would
be to identify these T cell subsets.
Other questions remain open concerning CNS inﬂammatory
responses in general, and NPSLE in particular; what about the
precise role played by microglia? And what about “glial auto-
phagy”, as this mechanism may be essential to preserve cellular
vesicles and proteins, notably mitochondrial architecture during
inﬂammation in astrocytes, and as such, neuronal homeostasis? Is
glial autophagy a target for speciﬁc therapy? Concerning therapy,
which immune-based treatment should be investigated in neuro-
psychiatric autoimmune diseases to foster CNS repair? Are smallnism
aemia
ncy
rednisolone doses over 7.5e10 mg/day)b
medication (e.g. cyclophosphamideb, azathioprine, mycophenolate mofetil)
mab)
rapy
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tools for treating patients with NPSLE and other NP autoimmune/
inﬂammatory diseases? Finally, how are autoimmunity, neurology,
and psychiatry intertwined?
8. Conclusions
The etiology of autoimmune and NP diseases, especially NPSLE,
is still fragmented and incomplete. Immunological, hormonal and
environmental factors undoubtedly interact to induce disease in
genetically-predisposed individuals. A disruption of BBB integrity
caused by external factors, including infections, is a pivotal factor in
the etiopathology of NPSLE in allowing the penetration of Abs into
the brain and binding to cross-reactive epitopes.
There is much current interest in the idea that gut microbiota
contributes to the autoimmune status of individuals and therefore
to behavioural defect. This idea remains however difﬁcult to
analyze deeply in humans since the commensal microbiota can
either be altered due to the disease itself or treatment. The use of
animal models where the intestinal ﬂora can be manipulated rep-
resents an experimental strategy of choice to investigate this cen-
tral mechanistic question. Some studies have shown that, in
patients suffering from myalgic encephalomyelitis/Chronic fatigue
syndrome, translocation of bacterial LPS from the gut and
engagement with TLRs (further acting as PAMPs) due to modiﬁca-
tion of intestinal permeability generated by molecules of chronic
inﬂammation (cytokines, NFKB, O&NS), may be source for fatigue
and depression [43,134,135].
The theory of “early-life programming of adult disease”, which
supposes that prenatally or early postnatally environmental factors
lead to permanent modiﬁcations in physiology throughout life is
now well accepted [136], and happens also for the immune system
[137]. Then, prenatal maternal exposure of rats to LPS or IL-6
signiﬁcantly increases central and peripheral proinﬂammatory
mediators amounts, along with an increase of the microglial den-
sity in the progeny, which persist until adulthood [138,139]. Contact
with infectious pathogens and/or immune activation early in life,
may also raise the risk of developing NP disorders later. From a
molecular point of view, data emphasise the role of prenatal
cytokine-related inﬂammatory mechanisms in the mediation of
maternal infection effects on the offspring; thus, both genetic and
pharmacological blockage of IL-6 in murine pregnant maternal
host, or a genetically-induced over-expression of IL-10, prevent the
long-term deleterious effects of prenatal viral-like immune acti-
vation, both at the cerebral and behavioural levels [140].
Finally, historically considered as an immune-privilege site, the
brain is presently viewed as being able to display immune reactions
[141e144]. Indeed, the brain presents functional lymphatic vessels,
located in the meninges, which remove ﬂuid and immune cells.
Then, dysfunction of this meningeal lymphatic system may drive
numerous neurological and neuroinﬂammatory conditions
(including NPSLE), in which modiﬁed immunity plays crucial role.
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